All journal articles

Storage & handling

Peptide aggregation: how to detect it, and why one test is not enough

What peptide aggregation is, what drives it, why it makes assay data vary, and what SEC, DLS and thioflavin T can and cannot detect.

  • Thistle BioLabs
  • 10 min read
  • Published
  • Updated

Research-use notice: this article is for legitimate laboratory and educational research only. It does not provide guidance for human use, administration, dosing or treatment.

Peptide aggregation is the self-association of peptide molecules into larger species, from small, reversible oligomers to amorphous clumps and ordered amyloid fibrils. No single analytical method sees every size and type of aggregate, so laboratories combine methods such as size-exclusion chromatography (SEC), dynamic light scattering (DLS) and thioflavin T (ThT) fluorescence, each of which answers a different question. Aggregation also changes how much free peptide an assay actually contains, which can make it a hidden source of variability between experiments.

What is peptide aggregation?

Aggregation is a physical change rather than a chemical one: the sequence stays the same, but the molecules stick to each other. A 2017 review in Interface Focus by Zapadka and colleagues describes self-association into either amorphous aggregates or highly structured fibrillar species, and reviews the factors that drive both in peptides.

Aggregates differ in more than size. In a 2006 review in The AAPS Journal, Philo points out that aggregate sizes run from small oligomers to visible “snow” and precipitates, that generally only the smaller species are reversible, and that aggregates also have a broad spectrum of lifetimes, which has important consequences for how they can be detected. He also notes that the measurement itself may destroy or create aggregates.

Regulators treat aggregates as impurities. The International Council for Harmonisation (ICH) specification guideline for biotechnological products, Q6B, classes aggregates, “dimers and higher multiples of the desired product”, as product-related impurities that are generally resolved from the product and quantified by appropriate analytical procedures. It names SEC and capillary electrophoresis as examples.

Most of this methods literature was written for protein medicines, with amyloid-forming peptides such as amyloid-beta as the main peptide examples. The principles transfer to synthetic research peptides, but the behaviour of any one sequence has to be measured, not assumed.

What makes peptides aggregate?

The Zapadka review discusses both intrinsic and external factors, which fall into three broad groups:

  • Intrinsic and solution factors: sequence, concentration, pH, net charge, excipients, chemical degradation and modification, and impurities.
  • Surfaces and interfaces: for example container walls and air–liquid interfaces.
  • Physical stresses: pressure, temperature, agitation and lyophilisation (freeze-drying).

Freezing and thawing a solution adds another stress. In one of Philo’s case studies, freeze–thaw stress generated transient, metastable oligomers that were “extremely sticky and difficult to measure by SEC”. Handling history therefore belongs in the experimental record, as our peptide storage guide explains, and chemical degradation such as methionine oxidation can feed into aggregation as well as being a problem in its own right.

Why aggregation makes assay data vary

An experiment is usually designed around a nominal concentration of peptide. If part of that peptide has aggregated, the amount of free, accessible peptide is lower than the calculation assumes, and aggregates may behave differently in the assay from the free peptide. If the extent of aggregation differs between vials, days or operators, the data will vary for reasons that have nothing to do with the variable being studied.

Sample preparation can make this worse or hide it. Filtering or centrifuging a solution can remove large aggregates before measurement, and diluting a sample can shift the balance between reversible oligomers and free peptide. Aggregation is also easily confused with adsorption to labware, since both reduce the amount of free peptide that a later measurement finds.

How is peptide aggregation detected?

Each common method measures a different physical property, so each has blind spots.

Method What it measures Watch out for
Size-exclusion chromatography (SEC) Separates species by size as they pass through a porous column, so monomer and aggregates elute as separate peaks Large aggregates can be filtered out and overlooked; sticky or short-lived oligomers can be lost or broken up on the column
Dynamic light scattering (DLS) How fast particles diffuse in solution, converted into a hydrodynamic size Very sensitive to small numbers of large particles, but qualitative rather than quantitative
Thioflavin T (ThT) fluorescence A dye whose fluorescence rises sharply when it binds amyloid-type fibrils Selective for fibrils rather than amorphous aggregates; other compounds can bias the reading
Analytical ultracentrifugation (AUC) How species sediment under high centrifugal force Specialist equipment; often used as a reference to check other methods

Size-exclusion chromatography

SEC is the workhorse for quantifying soluble aggregates, but it can mislead in both directions. A 2011 commentary in Pharmaceutical Research by den Engelsman and colleagues warns that large protein aggregates “may disappear and be overlooked” because column frits can filter them out. Philo describes the opposite error: an “aggregate” seen by SEC in stressed samples turned out to be a partially denatured monomer when checked by SEC with multi-angle light scattering and by sedimentation velocity, a form of AUC. In his freeze–thaw case, sedimentation velocity served as the reference used to develop a much improved SEC method.

Dynamic light scattering

DLS measures how quickly particles diffuse in solution; a 2016 practical guide in Biophysical Reviews by Stetefeld and colleagues explains how the diffusion coefficient gives the hydrodynamic radius and how DLS is used to check sample homogeneity. Den Engelsman and colleagues give its range as particles from about 1–2 nm to 3–5 µm in diameter and describe its sensitivity to large particles as unsurpassed, but note that “DLS yields qualitative results, not quantitative results”. It is a good early warning that something large is present, not a measure of how much.

Thioflavin T fluorescence

ThT is a dye whose fluorescence changes when it binds amyloid fibrils. In a 1993 study in Protein Science, LeVine showed that ThT reacted with aggregated fibrils of synthetic amyloid-beta peptides but not with monomeric or dimeric peptide, and that insulin fibrils also fluoresced intensely. That makes ThT well suited to following fibril formation over time.

Its limits are just as well documented:

  • Selectivity. A 2008 review of extrinsic fluorescent dyes in Pharmaceutical Research notes that ThT has a higher selectivity for fibril structures, whereas the dye 8-anilinonaphthalene-1-sulfonate (ANS) also interacts with hydrophobic areas in amorphous aggregates. A flat ThT signal does not rule out non-fibrillar aggregation.
  • Interference. A 2009 study in The FEBS Journal found that curcumin and quercetin significantly biased ThT readings, and that resveratrol did so too, although it is not spectroscopically active at the wavelengths of ThT fluorescence. The authors recommend testing for interference whatever a compound’s spectroscopic properties.
  • The dye can take part. The same 2008 review notes that a dye can itself promote or inhibit aggregation. A 2017 study in Royal Society Open Science found little effect of ThT on aggregation at concentrations of 20 µM or lower, while concentrations of 50 µM or more could change the shape of aggregation curves, in a protein-dependent way.
  • Binding is not fully understood. A 2010 review in the Journal of Chemical Biology describes models of how ThT binds fibrils as incomplete and conflicting.

Mass spectrometry approaches

Research groups are also using mass spectrometry to follow aggregation at the level of individual residues. A 2025 study in ACS Chemical Neuroscience by Kuang and colleagues used chemical footprinting with glycine ethyl ester (GEE), combined with kinetic modelling, to track conformational changes in amyloid-beta 1–42 as it aggregated. It identified the middle and C-terminal regions as the main aggregation sites. This is a specialist method on one model peptide, but it shows how much a simple concentration reading can miss.

Designing a study around aggregation

Den Engelsman and colleagues state the core point directly: since no single technique covers the full size range of aggregates, “a combination of several techniques is necessary”. Practical steps that follow from the literature above:

  • Match methods to the question. SEC for soluble oligomers you need to quantify, DLS as an early check for large species, and ThT only where fibrils are the question.
  • Measure at the start. Characterise the material at time zero, in the same buffer and container used for the experiment, so later changes have a baseline.
  • Run interference controls. For ThT work, include dye-only and test-compound-only controls alongside the peptide samples.
  • Record handling. Log freeze–thaw events, agitation, filtration, centrifugation and time in solution, because each can create or remove aggregates.
  • Keep the material consistent. Use the same batch across comparison arms and check its identity and purity on the batch laboratory report or certificate of analysis (COA); see HPLC vs mass spectrometry and How to read a peptide COA.

A note on evidence level: the studies cited here are analytical and methods research, carried out in vitro on proteins and model peptides. They describe how measurements behave, not the properties of any particular research peptide.

Peptide aggregation FAQs

What is peptide aggregation?

The self-association of peptide molecules into larger species, from small oligomers to amorphous aggregates and amyloid fibrils. The sequence is unchanged, but the physical state of the material is not.

What causes peptides to aggregate?

Reviews list sequence, concentration, pH, net charge, impurities and chemical degradation, plus surfaces, temperature, agitation, freeze–thaw and freeze-drying. Which factors matter depends on the peptide.

How do you test for peptide aggregation?

With a combination of methods, because none covers every size and type. Common choices are SEC, DLS and, for amyloid fibrils, ThT fluorescence, with analytical ultracentrifugation as a reference method.

Does thioflavin T detect all aggregates?

No. ThT is selective for amyloid-type fibrils and can miss amorphous aggregates, and other compounds in a sample can bias its fluorescence.

Is peptide aggregation reversible?

Sometimes. Philo notes that generally only the smaller aggregate species are reversible; larger aggregates and fibrils usually are not.

Sources

Published by Thistle BioLabs, a UK supplier of research materials. This article summarises external research, not studies conducted by Thistle. Educational information only; no medical advice or recommendation for personal use.

Educational information only. This journal does not recommend a substance for personal use or provide medical advice.